LRP11-AS1 promotes the proliferation and migration of triple negative breast cancer cells via the miR-149-3p/NRP2 axis

Background Breast cancer is the most commonly diagnosed cancer in women. Triple negative breast cancer (TNBC) is the most difficult subtype of breast cancer to treat due to the deficiency in drug-targetable receptors. LRP11-AS1, a newly identified oncogenic long noncoding RNA (lncRNA) was found to be significantly overexpressed in TNBC cells. The aim of this study is to investigate the malignant roles and the oncogenic mechanisms of LRP11-AS1 in TNBC. Methods CCK-8, colony formation, transwell migration and transwell invasion assays were performed to study the functions of LRP11-AS1. Quantitative PCR and western blot were used to determine the gene expression. Bioinformatics analysis and dual-luciferase reporter assay were conducted to study lncRNA and miRNA interactions. Results LRP11-AS1 was found to be significantly overexpressed in TNBC cells compared to the non-TNBC cells and normal mammary epithelial cells. Knockdown of LRP11-AS1 could inhibit the growth and metastasis of TNBC cells and regulate cell cycle. Mechanistically, LRP11-AS1 was found to act as a competing endogenous RNA (ceRNA) to sponge miR-149-3p. Silencing of LRP11-AS1 increased the expression of miR-149-3p and overexpression of miR-149-3p suppressed the expression of LRP11-AS1. Inhibition of miR-149-3p could reverse the anticancer effect of LRP11-AS1 deficiency in TNBC cells. Moreover, Neuropilin-2 (NRP2) was found to be the target of miR-149-3p. Rescue experiments revealed that NRP2 overexpression could rescue the anticancer effect of LRP11-AS1 deficiency in TNBC cells. Conclusion LRP11-AS1 overexpressed in TNBC showed the oncogenic effects possibly by sponging miR-149-3p and regulating the miR-149-3p/NRP2 axis, which indicated LRP11-AS1 as a potential diagnostic biomarker and therapeutic target in TNBC. Supplementary Information The online version contains supplementary material available at 10.1186/s12935-022-02536-8.


Background
Breast cancer is the most frequently diagnosed cancer in women. In 2020, female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimation of 2.3 million new cases, leading to the death of 680,000 patients worldwide [1]. Treatment of breast cancer is a multidisciplinary management, including surgery, radiation and medical therapy. Medical treatment such as chemotherapy, endocrine therapy or HER-2 directed therapy is determined by factors including disease stage, hormone receptor status, lymph node involvement and tumor size [2]. Triple negative breast cancer (TNBC) is a subtype of breast cancer defined by a deficiency in estrogen, progesterone and HER2 receptors. TNBC was highly aggressive with high recurrence and organ metastasis rate. Due to the lack of drug-targetable receptors, chemotherapy is the only recommended systemic treatment of TNBC, inevitably with resistance and relapse. New diagnostic biomarkers and drug targets are needed for the treatment of this type of breast cancer [3,4].
LncRNAs are long noncoding RNAs with more than 200 nucleotides, functioning as master regulators of gene expression in various biological events and disease processes including cancer. They could regulate the targeted genes in the transcriptional or post-transcriptional levels [5]. A recent "competing endogenous RNA (ceRNA)" hypothesis proposed that lncRNA could regulate gene expression by sequestering microRNAs (miRNAs) to control their concentration within the cell and act as a negative regulator of miRNAs and therefore, a positive regulator of the targeted gene expression [6,7]. ENSG00000273132, located at chromosome 6 is a novel long noncoding RNA (lncRNA) antisense to low-density lipoprotein (LDL) receptor related protein 11 (LRP11). We here named it LRP11 antisense RNA 1 (LRP11-AS1). This lncRNA was reported to be overexpressed in papillary thyroid cancer [8]. However, to date, the expression of LRP11-AS1 in other cancer apart from thyroid cancer has not been investigated. We analyzed the expression of LRP11-AS1 in the cell lines of different cancer types. Interestingly, we found that LRP11-AS1 was significantly overexpressed in TNBC cells as compared to the non-TNBC cells and the normal mammary epithelial cells. The roles of LRP11-AS1 played in TNBC and the possible mechanisms of its oncogenic behavior are therefore investigated here.
On the basis of target prediction using bioinformatics analyses, LRP11-AS1 may serve as a ceRNA for miR-149-3p. miR-149-3p was reported to be a tumor suppressive miRNA in breast cancer. The expression of miR-149-3p was reported to be decreased in the clinical samples of breast cancer. Inhibition of miR-149-3p could promote the proliferation, invasion and migration of breast cancer cells [9,10]. Moreover, online bioinformatics analysis tool TargetScan (http:// www. targe tscan. org/ vert_ 72/) predicted Neuropilin-2 (NRP2) as one potential target of miR-149-3p. NRP2 is a member of neuropilin family, which are cell surface antigens that bind to vascular endothelial growth factor (VEGF). NRP2 was found to be involved in multiple cellular physiological functions including proliferation, angiogenesis and migration [11][12][13]. It was found to be overexpressed in invasive breast cancer and TNBC, and was correlated with lymph node metastasis [12,14].
In this work, we explored the relationships among LRP11-AS1, miR-149-3p and NRP2 in triple negative breast cancer cells. Our findings may provide a potential diagnostic biomarker and therapeutic target in TNBC.

Cell proliferation and colony formation assay
A total of 5000 cells/well in 100 μL of culture media were seeded in the 96-well plate. CCK-8 reagent (HB-CCK8-1, Hanbio Biotechnology, China) was used to determine cell proliferation according to the manufacturer's instructions. OD450 was determined at different time points (day 0, 1, 2,3 and 4 for the knockdown study and day 0, 1, 2 and 3 for the overexpression study) after CCK-8 incubation. Colony formation was performed by seeding cells in 6-well plate and allowed to grow for 8 days followed by fixing with methanol and staining with crystal violet. The cell number seeded in the well was as follows: A number of 5000 cells/well of MDA-MB-468 cells were seeded. A number of 3000 cells/well of MDA-MB-231 cells were seeded except for the LRP11-AS1 overexpression experiment, 2000 cells/well were seeded. The media used in the colony formation assay were 2 mL/well.

Wound healing assay
A total of 4 × 10^5 cells/well of transfected MDA-MB-231 cells or a total of 6 × 10^5 cells/well of transfected MDA-MB-468 cells were seeded in 12-well plate for 24 h. Wound was scratched using a 100μL tip. The cells were allowed to migrate for 24 h. Images were taken at 0 h and 24 h after wound scratching.

RNA extraction, reverse transcription and quantitative PCR (qPCR)
Extraction of total RNA and miRNA was conducted using RNA extraction kit (DP419, DP501, Tiangen, China). Reverse transcription of total RNA and miRNA was conducted using reverse transcription kits (RR037A, Takara and KR211, Tiangen). qPCR was performed using LightCycler 480 instrument (Roche) and SYBR green qPCR kit (AG11701, Accurate Biology, China). The primers used in the qPCR assays were:

Flow cytometry
A total of 1 × 10^5 cells/well were seeded in 12-well plate for 24 h before transfection with smart silencer for 72 h followed by cell cycle analysis using cell cycle analysis kit from BD (550825). BD FACSCanto II flow cytometry was used as assay system.

Dual-luciferase reporter assay
Fragments of LRP11-AS1 containing the binding site of miR-149-3p or the mutant sequence were synthesized and sub-cloned into the pmirGLO dual-luciferase reporter plasmid (GENEWIZ, China). Cells were seeded in 24-well plate at a density of 5 × 10^4 cells/ well for 24 h before co-transfection with miR-149-3p mimics or mimics NC and the wild type dual-luciferase reporter plasmid or the mutant plasmid. Luciferase activity was determined at 48 h post-transfection using the Dual-Luciferase Reporter Assay System (E1910, Promega). Fragments of the 3′-untranslated region (3′'-UTR) of NRP2 containing the binding site of miR-149-3p or the mutant sequence were synthesized and sub-cloned into the pmirGLO dual-luciferase reporter plasmid (GENEWIZ, China). Other experiment conditions were the same.

Statistical analysis
All quantitative results were presented as the mean ± standard deviation (SD). The Student's t-test (two-sided) was used to compare the statistical significance between two groups using Prism. Differences were considered significant as *P < 0.05; **P < 0.01, ***P < 0.001.

LRP11-AS1 promoted the growth and metastasis of TNBC cells and regulated cell cycle
In our previous research, LRP11-AS1 was found to be an oncogenic lncRNA in thyroid cancer. The role of LRP11-AS1 in breast cancer was investigated here. As shown in expression of p21 in MDA-MB-468 was low ( Fig. 1J and  1K). The effect of LRP11-AS1 on the metastasis of TNBC cells was evaluated. Knockdown of LRP11-AS1 inhibited the migration and invasion of TNBC cells ( Fig. 1L and Additional file 1: Fig. S4). Overexpression of LRP11-AS1 promoted the migration and invasion of TNBC cells ( Fig. 1M and Additional file 1: Fig. S5). Knockdown of LRP11-AS1 also inhibited the wound healing migration of TNBC cells (Additional file 1: Fig. S6). These results suggested that LRP11-AS1 could promote the growth and migration of TNBC cells and also regulate cell cycle.

miR-149-3p was the target of LRP11-AS1 in TNBC
Bioinformatics analysis was performed to investigate the possible binding target of LRP11-AS1. The possible interacting miRNAs were predicted by LncRNASNP2 (http:// bioin fo. life. hust. edu. cn/ lncRN ASNP# !/) and the miRNAs with binding energy less than -20 were shown in Additional file 1: Fig. S7. After searching the biological functions of these miRNAs, miR-149-3p, miR-338-3p and miR-4508 were selected for further study since they were reported to be involved in cell growth, migration or as a tumor suppressive miRNA in breast cancer [9,15,16]. Figure 2A showed  (Fig. 2B). Moreover, overexpression of miR-149-3p in TNBC cells suppressed the expression of LRP11-AS1 (Fig. 2C). Knockdown of LRP11-AS1 did not regulate the expression of miR-338-3p nor miR-4508, which were not investigated further. Dual-luciferase reporter assay was performed to investigate the binding between LRP11-AS1 and miR-149-3p. Figure 2D exhibited the possible binding sequence between LRP11-AS1 and miR-149-3p predicted by bioinformatics analysis. Figure 2E and F indicated that miR-149-3p could bind to LRP11-AS1 at the predicted binding site. These results indicated that miR-149-3p was a target of LRP11-AS1 in TNBC cells.

Overexpression of miR-149-3p inhibited the growth and metastasis of TNBC cells
The effect of miR-149-3p on the growth and metastasis of TNBC was investigated. miR-149-3p was overexpressed in TNBC cells (Fig. 3A). Figure 3B and C showed that overexpression of miR-149-3p inhibited the proliferation of TNBC cells. Figure 3D and E showed that inhibition of miR-149-3p by inhibitors enhanced the proliferation of TNBC cells. Moreover, overexpression of miR-149-3p inhibited the colony formation (Fig. 3F), migration and  Fig. S8).

miR-149-3p inhibition reversed the anticancer effect of LRP11-AS1 deficiency in TNBC cells
Rescue experiments were performed to investigate whether LRP11-AS1 promoted the growth and metastasis of TNBC cells by targeting miR-149-3p. Inhibition of miR-149-3p partially reversed the inhibitory effect of LRP11-AS1 deficiency on cell proliferation ( Fig. 4A and B) and colony formation (Fig. 4C) in TNBC cells. Figure 4D exhibited that inhibition of miR-149-3p partially restored the inhibitory effect of LRP11-AS1 knockdown on the migration and invasion of TNBC cells. These results indicated that knockdown of LRP11-AS1 inhibited the growth and metastasis of TNBC cells by targeting miR-149-3p. magnification. Data were presented as mean ± SD. Statistic significant differences were indicated as *P < 0.05, **P < 0.01, ***P < 0.001

NRP2 was a target of miR-149-3p and LRP11-AS1 regulated NRP2 through miR-149-3p
The downstream targets of miR-149-3p were predicted using online bioinformatics analysis tool TargetScan (http:// www. targe tscan. org/ vert_ 72/). The top 10 predicted targets were listed in Additional file 1: Fig. S9. The expression of the top 3 targets was measured after the overexpression of miR-149-3p. The expression of the 3 targets were not significantly affected. Five more targets of miR-149-3p were selected among the top 2000 predicted targets according to TargetScan. These genes were TP53, AKT2, MMP2, FOXC2 and NRP2, which were reported to be involved in the proliferation, migration or invasion of cancers. Among these 5 predicted targets, Neuropilin-2 (NRP2) was the only gene found to be regulated by miR-149-3p. Figure 5A showed the relative expression of NRP2 in different cell lines. TNBC cell line MDA-MB-231 and MDA-MB-468 showed higher expression of NRP2 compared to the non-TNBC cell line MCF7 and mammary epithelial cell line MCF10A. Figure 5B represented the possible binding site on the 3′-untranslated region (UTR) of NRP2 to miR-149-3p. Dual-luciferase reporter assay indicated the binding of miR-149-3p to NRP2 at the predicted binding site (Fig. 5C and D).
Overexpression of miR-149-3p downregulated the mRNA (Fig. 5E) and protein ( Fig. 5F and G) levels of NRP2 in TNBC cells. Silencing of LRP11-AS1 inhibited the mRNA (Fig. 5H) and protein ( Fig. 5I and J) expression of NRP2 in TNBC cells. Rescue experiments indicated that inhibition of miR-149-3p restored the suppression of NRP2 by LRP11-AS1 knockdown in both of the transcriptional ( Fig. 5K and L) and translational ( Fig. 5M and  5N) levels. These results suggested that NRP2 was a target of miR-149-3p and NRP2 was regulated by LRP11-AS1 through miR-149-3p.

Overexpression of NRP2 reversed the anticancer effect of LRP11-AS1 deficiency in TNBC cells
Since NRP2 was determined to be the target of miR-149-3p and was regulated by LRP11-AS1, rescue experiments were performed by overexpressing NRP2 in TNBC cells. Figure 6A showed the overexpression of NRP2 in MDA-MB-231 cells. The overexpression of NRP2 in MDA-MB-468 was insignificant. Overexpression of NRP2 partially rescued the inhibitory effect of LRP11-AS1 deficiency on cell proliferation (Fig. 6B). Overexpression of NRP2 also partially rescued the inhibitory effect of LRP11-AS1 deficiency on the colony formation (Fig. 6C), migration and invasion (Fig. 6D) of TNBC cells. These results indicated that knockdown of LRP11-AS1 inhibited the growth and metastasis of TNBC cells by inhibiting NRP2. LRP11-AS1 that was overexpressed in TNBC cells promoted the growth and metastasis of TNBC cells by targeting the miR-149-3p/NRP2 axis.

Discussion
Triple negative breast cancer (TNBC) is a very aggressive subtype of breast cancer characterized by a deficiency in the hormone receptors, which could serve as drug targets. Chemotherapy is the only recommended systemic treatment with inevitable resistance or relapse. In this study, lncRNA LRP11-AS1 was firstly reported to be overexpressed in TNBC cells compared to the non-TNBC cells and normal mammary epithelial cells. Functional studies suggested that silencing of LRP11-AS1 inhibited the growth and metastasis of breast cancers and induced cell cycle arrest. Mechanistically, miR-149-3p was predicted to be the target of LRP11-AS1 by bioinformatics analysis. miR-149-3p was previously reported to be downregulated in breast cancer clinical samples [9,17]. In our study, low expression of miR-149-3p was found in TNBC cell lines. Overexpression of miR-149-3p could inhibit the growth and metastasis of TNBC, which indicated the tumor suppressive role of miR-149-3p in TNBC cells. Dualluciferase reporter assay proved the binding of LRP11-AS1 with miR-149-3p in the predicted binding site. More importantly, knockdown of LRP11-AS1 increased the expression of miR-149-3p and overexpression of NRP2 was previously reported as a member of the membrane protein neuropilin family. Increased expression of NRP2 was found in invasive and TNBC and was correlated with lymph node metastasis [12,14,18,19]. In our study, dual-luciferase reporter assay revealed the interaction between miR-149-3p and the 3′-UTR of NRP2. miR-149-3p mimics could inhibit the expression of NRP2 in TNBC cells. Moreover, silencing of LRP11-AS1 could also inhibit the expression of NRP2 in TNBC cells. Rescue experiments represented that inhibition of miR-149-3p could restore the inhibited expression of NRP2 by LRP11-AS1 knockdown, indicating that LRP11-AS1 regulated NRP2 expression through miR-149-3p. Functionally, overexpression of NRP2 could partially reverse the anticancer effect of LRP11-AS1 deficiency on the proliferation, migration and invasion of TNBC cells. Figure 7 represented a graphic description of the possible mechanisms of the oncogenic role of LRP11-AS1 played in TNBC. In our results, bioinformatics analysis predicted the possible binding sequence between LRP11-AS1 and miR-149-3p (Fig. 2D) and knockdown of LRP11-AS1 could promote the expression of miR-149-3p (Fig. 2B). The overexpression of LRP11-AS1 in TNBC lead to the suppression of miR-149-3p and the upregulation of NRP2, which resulted in the promotion of the growth and metastasis of TNBC cells. LRP11-AS1 exhibited the tumorigenic effect in TNBC by sponging miR-149-3p and targeting the miR-149-3p/NRP2 axis. LRP11-AS1 could serve as a potential biomarker in the diagnosis and treatment of TNBC. Limitations still exist in this study, even though TNBC cell lines overexpress LRP11-AS1, the expression of this lncRNA in TNBC clinical samples needs investigation. After validating the function of LRP11-AS1 in vitro, the role and mechanism of this novel lncRNA could be further studied in vivo in the future research.

Conclusions
LncRNA LRP11-AS1, which was overexpressed in TNBC cells could promote the growth and metastasis of TNBC cells by working as a ceRNA to sponge miR-149-3p and regulating the miR-149-3p/NRP2 axis, indicating LRP11-AS1 as a potential biomarker in the diagnosis and treatment of TNBC.
Additional file 1. Additional figures.